Diogo Rau compensation by year
ELI LILLY Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $412,308 |
| Bonus | $250,000 |
| Stock awards | $4,000,000 |
| Option awards | $0 |
| Non-equity incentive | $362,831 |
| Pension and deferred compensation | $44,519 |
| All other | $31,670 |
| Total | $5,101,328 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ELI LILLY & Co DEF 14A filed March 18, 2022, accession 0000059478-22-000099, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ELI LILLY & Co filed document, accession 0000059478-22-000099. Every figure is read from that document and cited to the page and table it appears in. Filed March 18, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 20,160 | $5,568,595 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in ELI LILLY & Co's FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2021 proxy (filed March 18, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-09 | Grant or award | — | 4,599.16 | $1044.67 | 26,396.53 |
| 2026-02-09 | Grant or award | — | 4,432.32 | $1044.67 | 26,229.69 |
| 2026-02-01 | Tax withholding | — | 1,673.54 | $1037.15 | 21,797.37 |
| 2026-02-01 | Exercise or conversion | — | 3,752 | $0.00 | 23,470.91 |
| 2026-02-01 | Exercise or conversion derivative | — | 3,752 | $0.00 | 0 |
| 2025-02-10 | Grant or award | — | 6,815.2 | $868.88 | 19,718.91 |
| 2025-02-10 | Grant or award derivative | — | 3,752 | $0.00 | 3,752 |
| 2025-02-01 | Tax withholding | — | 1,466.29 | $811.08 | 12,903.71 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ELI LILLY’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| David Ricks | Chair, President, and CEO | $21,509,985 |
| Daniel Skovronsky | Senior Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | $7,527,092 |
| Jacob Van Naarden | Senior Vice President, CEO Loxo Oncology at Lilly and President, Lilly Oncology | $6,122,742 |
| Diogo Rau · this page | Senior Vice President and Chief Information and Digital Officer | $5,101,328 |
| Anat Ashkenazi | Senior Vice President and Chief Financial Officer | $4,657,609 |
| Anat Hakim | Executive Vice President, General Counsel and Secretary | $4,017,853 |
| Joshua Smiley | Former Senior Vice President and Chief Financial Officer | $244,681 |
The full ELI LILLY compensation record
free company briefThis page is one person within ELI LILLY's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ELI LILLY proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ELI LILLY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.